Drugs / 4-peptide melanoma vaccine
last change Mar 2016 re-read 2 minutes ago

4-peptide melanoma vaccine

Vaccine

Developed for
melanoma
Investigated by
Eisai Inc. · University of Chicago

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00515528 Apr 2007 → Mar 2016 melanoma University of Chicago Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 4-peptide melanoma vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00515528
Modality Vaccine “Experimental cancer vaccine given as a shot under the skin once every two weeks” NCT00515528
Route Subcutaneous “injected intra-dermally or subcutaneously on day 1” NCT00515528